Esra Ozbasli医師は、産婦人科における_doctor_8319_年以上の専門的な経験を活かし、高度な性器形成術および低侵襲レーザー治療に重点を置いています。
メリムスキー教授は、ソラスキー医療センターの軟部組織および骨腫瘍科を率いており、高度なレーザー手術技術を専門としています。
ソラック医師は、ハジェテペ大学やMDアンダーソンがんセンターなど、トップクラスの機関で訓練を受けた、様々な癌に対するレーザー手術の専門家です。
ダン・グリサロ教授は、スラスキー医療センターの婦人科腫瘍学部門を率いており、がんのレーザー手術を専門としています。
タフシン・オザトリ准教授は、イスティニエ・リヴ大学病院にて乳がん、肺がん、消化器がんを専門としています。
アレムダル医師は、アクデニズ大学で広範なトレーニングを受けた医療腫瘍学の専門家です。内科および腫瘍学において_doctor_9570_年以上の経験を有しています。
ヤーコフ・ローレンス医師は、シェバ医療センターの放射線腫瘍科部長です。精密放射線治療と神経腫瘍学を専門としています。ローレンス医師は、膵臓がんの疼痛管理のための腹腔神経叢ラジオサージェリー（放射線外科）の先駆者です。専門分野における最高の名誉の一つであるFASTROの称号を保持しています。
ヤイール・バー博士は、シェバ医療センターの癌センターの副所長であり、胸部腫瘍内科医です。進行非小細胞肺癌の治療において、個別化免疫療法および標的療法を専門としています。分子生物学の博士号（PhD）を取得しており、免疫療法耐性に焦点を当てた研究室を主導しています。
ニール・クラインマン医師は、シェバ医療センターの結石・内視鏡泌尿器科ユニットを統括しています。複雑な腫瘍に対する腎温存レーザー手術のパイオニアです。フォーブス誌とResultMedにより、2025年および2026年のイスラエルのベストドクターに選出されました。クラインマン医師は、がん治療中に臓器機能を維持するための独自のデュアルレーザーシステムを使用しています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
トゥンカイ・タシュ医師は、イスタンブールのSafe Urologyクリニックの泌尿器科外科医です。P-Shotの応用に関する結果を発表した世界で最初の5人の医師の一人です。タシュ医師は泌尿器腫瘍学と男性の性機能健康を専門としています。ドイツのハイデルベルク大学でフェローシップを修了しました。彼の診療は、再生医療とがんのロボット手術に重点を置いています。
カイザス教授は、頭頸部がんに対する経口的レーザー切除術に関する国際的な臨床試験を主導しており、外科的精度と最先端のレーザー技術を融合させています。
Gül Alço教授は、約27年の経験を持つ放射線腫瘍医です。乳がん、肺がん、前立腺がん、消化器がん、婦人科がん、中枢神経系腫瘍、頭頸部がん、軟部組織腫瘍、骨腫瘍の放射線治療を行っています。
専門分野は、適応放射線治療とラジオサージャリー（放射線外科）です。高度な放射線技術を駆使し、患者中心の多職種連携環境において、個別化された科学的根拠に基づくケアを提供しています。
アブドラ・サキン教授（Prof. Dr. Abdullah Sakin）は、腫瘍内科の教授です。肺がん、乳がん、消化器がん、泌尿器がん、婦人科がん、頭頸部がん、悪性黒色腫（メラノーマ）などの固形腫瘍を専門としています。
科学的根拠に基づいた個別化医療を提供しています。治療法には、化学療法、分子標的療法、免疫療法、ホルモン療法、精密腫瘍学（プレシジョン・オンコロジー）が含まれます。200本以上の科学論文を執筆しており、国際的な臨床研究にも積極的に参加しています。これらの活動は、患者中心のがん医療の発展に寄与しています。
シュリダール・P.S.医師は放射線治療を専門としており、バナーラス・ヒンドゥー大学および国家試験委員会で広範なトレーニングを受けています。
30,000件以上のPET検査と1,000人の甲状腺がん患者の治療実績を持つBorde医師は、HCG Manavata Cancer Centreに核医学の広範な専門知識をもたらします。
シュルティ・ケイト医師は、免疫療法やメトロノーム療法などの高度な技術を用いて、肺がん、乳がん、婦人科がんの治療を専門としています。
アーマー・アリフ・シェイク医師は、口腔がん手術と機能的リハビリテーションを専門としており、臓器の温存と患者の治療成績の向上に重点を置いています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 23年の経験 | 性器美容レーザー治療 | レーザーを用いた膣若返り術および美容治療を専門とする。ダビンチロボット手術の認定を受けており、同分野の他の専門医の指導も行っている。 | トルコ | お問い合わせください | |
| #2 | 41年の経験 | 骨腫瘍および軟部組織腫瘍 | レーザー手術技術を用いた肉腫治療を専門とする。ソラスキー医療センター軟部組織および骨腫瘍科部長。ESMO肉腫ファカルティメンバー。 | イスラエル | から $950 | |
| #3 | 20年の経験 | 癌のレーザー手術 | 複数の癌に対するレーザー手術を専門とする。ハジェテペ大学およびMDアンダーソンがんセンターで訓練を受けた。 | トルコ | から $100 | |
| #4 | 32年の経験 | 婦人科がんのレーザー手術 | イスラエル屈指の病院の婦人科腫瘍学部門長。カナダで専門研修を受け、標的がん治療に関する多数の論文を発表。 | イスラエル | お問い合わせください | |
| #5 | 2016年の経験 | 乳がん、肺がん、消化器がん | 10年の経験を持つ乳がん、肺がん、消化器がんの専門医。2016年より准教授。 | トルコ | お問い合わせください | |
| #6 | 20年の経験 | 腫瘍学関連のレーザー治療 | 高度なトレーニングを受けた医療腫瘍学の専門家。トルコの主要な医療機関での豊富な病院勤務経験を有しています。 | トルコ | お問い合わせください | |
| #7 | 21年の経験 | 頭頸部レーザー手術 | 腫瘍学における国際的なレーザー手術試験の主任研究員。BJOMSの編集長であり、英国最大の口腔顎顔面外科ランダム化比較試験を主導している。 | キプロス | から €225 | |
| #8 | 30年の経験 | がんの放射線治療 | バナーラス・ヒンドゥー大学での高度なトレーニングを受けた放射線治療の専門家。神経腫瘍学会を含む複数の腫瘍学会の活動的な会員。 | インド | お問い合わせください | |
| #9 | 11年の経験 | 甲状腺がん治療 | 核医学を専門とし、30,000件以上のPET検査を実施。甲状腺がんに対する放射性ヨウ素治療の専門家。同分野で論文を発表している研究者。 | インド | お問い合わせください | |
| #10 | 15年の経験 | 高度な癌免疫療法 | 免疫療法やメトロノーム療法などの最先端の癌治療を専門としています。WCLC 2018で研究を発表し、タタ記念病院で研修を受けました。 | インド | お問い合わせください |